Life Sciences Times

Precision BioSciences Reports $32.7 Million Q2 Loss, Advances Gene-Editing Trials

Viridian Posts $127.1 Million Q2 Loss After Launching Thyroid Eye Disease Drug

Ironwood Raises 2026 Outlook as Q2 Revenue, Profit Climb

Agenus Reports $34.5 Million in Q2 Revenue, Advances Phase 3 Colon Cancer Trial

Insulet Faces Securities Lawsuit Over Omnipod Manufacturing Disclosures

Azenta Q3 Revenue Rises 12 Percent to $161 Million

Expedition Therapeutics Raises $115 Million, Begins Phase 2 COPD Trial

Charles River Laboratories Q2 Revenue Falls 3 Percent to $1 Billion

Obsidian Enrolls First Patient in Registration-Enabling Amsoki-cel Melanoma Cohort

Enveric Reports Preclinical Data Supporting Non-Hallucinogenic Profile of EB-003